| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Observational Study |
| Article Title |
Hepatitis C virus burden: Treating and educating people without prejudice
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Elettra Merola, Elisa Menotti, Giovanna Branz, Andrea Michielan, Sonia Seligmann, Annora Ratti, Flora Agugiaro, Luisa Moser, Giovanni Vettori, Anna Franceschini, William Mantovani, Riccardo Pertile, Giovanni de Pretis and Cecilia Pravadelli |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Andrea Michielan, MD, Doctor, Doctor, Department of Gastroenterology, Santa Chiara Hospital, Azienda Provinciale Per I Servizi Sanitari (APSS), Largo Medaglie D'oro 8, Trento 38122, Italy. andrea.michielan@apss.tn.it |
| Key Words |
Hepatitis C virus; Service for substance use disorder; Direct-acting antivirals; Sustained virologic response; Compliance; Tolerability |
| Core Tip |
HCV infection has an incidence of 1.1%, reaching 60% in Italy among people who inject drugs. This paper reports the impact of our HCV-dedicated program to provide antiviral treatment to HCV patients with a history of substance abuse. 40 patients were treated with direct-acting antivirals: 38 were receiving opioid agonist maintenance therapy, and 4 had just finished this treatment. 37.5% had a history of alcoholism, and 42.5% received concomitant psychiatric treatment. The therapy cycle was completed in all patients, and 92.5% adhered to post-therapy controls. All patients were HCV RNA-negative at the end of treatment, with a sustained virological response of 92.5%. |
| Publish Date |
2022-07-27 13:17 |
| Citation |
Merola E, Menotti E, branz G, Michielan A, Seligmann S, ratti A, Agugiaro F, Moser L, Vettori G, franceschini A, mantovani W, Pertile R, de Pretis G, Pravadelli C. Hepatitis C virus burden: Treating and educating people without prejudice. World J Hepatol 2022;14(7): 1495-1503 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i7/1495.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i7.1495 |
